Admission of Further Securities to Trading
2 November 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
|
1 |
Details of the issuer |
|
|
a) |
Name |
AstraZeneca PLC |
|
b) |
LEI |
PY6ZZQWO2IZFZC3IOL08 |
|
2 |
Details of the transferable securities admitted to trading |
|
|
a) |
Name, type and identification code |
Ordinary Shares of $0.25 each ISIN: GB0009895292 |
|
b) |
Regulated market |
London Stock Exchange - Main Market |
|
c) |
Number of further securities issued and admitted |
11,948 |
|
d) |
Total number of securities in issue following admission |
1,551,065,237 |
|
e) |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
3 |
Admission details |
|
|
a) |
Date of admission |
Issued between 1 October 2026 to 31 October 2026 (admitted under a block admission dated 29 January 2021) |
|
b) |
Prospectus information |
Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
|
|
c) |
Coverage of notification |
Admission of shares under the Company’s employee share schemes from 1 October 2026 up to 31 October 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares dated 29 January 2021. |
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE